Accessibility Menu
BioAge Labs Stock Quote

BioAge Labs (NASDAQ: BIOA)

$5.30
(-1.1%)
-0.06
Price as of October 21, 2025, 3:43 p.m. ET

KEY DATA POINTS

Current Price
$5.3
Daily Change
(-1.1%) $0.06
Day's Range
$5.26 - $5.52
Previous Close
$5.3
Open
$5.36
Beta
1.31
Volume
368,293
Average Volume
161,591
Market Cap
192.2M
Market Cap / Employee
$5.36M
52wk Range
$2.88 - $26.62
Revenue
-
Gross Margin
0.95%
Dividend Yield
N/A
EPS
-$2.24
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

BioAge Labs Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
BIOA-77.54%N/AN/A-71%
S&P+15.06%+95.03%+14.29%+17%

BioAge Labs Company Info

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Richmond, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$2.41M0.0%
Gross Profit$2.35M4904.1%
Gross Margin97.60%0.0%
Market Cap$148.06M0.0%
Market Cap / Employee$2.31M0.0%
Employees640.0%
Net Income-$21.56M-58.8%
EBITDA-$24.71M-62.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$220.33M38.5%
Accounts Receivable$0.60M0.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$2.52M-53.5%
Short Term Debt$6.23M-1.1%

Ratios

Q2 2025YOY Change
Return On Assets-32.48%0.0%
Return On Invested Capital-0.80%0.0%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$20.13M-27.3%
Operating Free Cash Flow-$19.97M-26.5%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-3.610.630.420.47-
Price to Sales92.9038.33-
Price to Tangible Book Value-3.610.630.420.47-
Enterprise Value to EBITDA-15.665.4510.695.68-
Return on Equity-30.2%-35.9%-
Total Debt$10.21M$8.70M$10.31M$8.75M-25.32%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.